×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:INO

Inovio Pharmaceuticals Stock Forecast, Price & News

$1.89
+0.16 (+9.25%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.72
$1.89
50-Day Range
$1.44
$3.09
52-Week Range
$1.38
$9.96
Volume
6.03 million shs
Average Volume
5.58 million shs
Market Capitalization
$432.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.80

Inovio Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
524.3% Upside
$11.80 Price Target
Short Interest
Bearish
15.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
1.31mentions of Inovio Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.19) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.23 out of 5 stars

Medical Sector

239th out of 1,428 stocks

Surgical & Medical Instruments Industry

28th out of 137 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Inovio Pharmaceuticals logo

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Stock News Headlines

The 3-Stock Retirement Blueprint
When most folks think about making money through the markets, they think “buy and hold.” They think “diversification.” And they think about investing in things like index funds. But one man has a different approach… It’s called the “3-Stock Retirement Blueprint.”
Stock Market Plunge: 2 Stocks to Avoid Right Now
The 3-Stock Retirement Blueprint
When most folks think about making money through the markets, they think “buy and hold.” They think “diversification.” And they think about investing in things like index funds. But one man has a different approach… It’s called the “3-Stock Retirement Blueprint.”
UPDATE 1-Inovio appoints Jacqueline Shea as CEO
Inovio Pharmaceuticals Inc. Q1 Loss increases, misses estimates
Inovio Pharmaceuticals Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INO
Employees
317
Year Founded
1979

Company Calendar

Last Earnings
5/10/2022
Today
7/02/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$11.80
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+524.3%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
5 Analysts

Profitability

Net Income
$-303.66 million
Net Margins
-20,479.29%
Pretax Margin
-20,347.16%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$1.90 per share

Miscellaneous

Free Float
221,483,000
Market Cap
$432.89 million
Optionable
Optionable
Beta
0.82

Social Links















Inovio Pharmaceuticals Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals
or view top-rated stocks.

What is Inovio Pharmaceuticals' stock price forecast for 2022?

5 Wall Street analysts have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their INO stock forecasts range from $3.00 to $35.00. On average, they predict Inovio Pharmaceuticals' stock price to reach $11.80 in the next year. This suggests a possible upside of 524.3% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Inovio Pharmaceuticals' stock performed in 2022?

Inovio Pharmaceuticals' stock was trading at $4.99 at the start of the year. Since then, INO shares have decreased by 62.1% and is now trading at $1.89.
View the best growth stocks for 2022 here
.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Inovio Pharmaceuticals
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.08. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.66 million. Inovio Pharmaceuticals had a negative net margin of 20,479.29% and a negative trailing twelve-month return on equity of 76.48%. The business's quarterly revenue was down 46.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) EPS.
View Inovio Pharmaceuticals' earnings history
.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals's stock reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • Dr. Jacqueline E. Shea Ph.D., CEO, Pres & Director (Age 56, Pay $698.85k)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 59, Pay $686.51k)
  • Dr. Laurent M. Humeau Ph.D., Chief Scientific Officer (Age 55, Pay $672.26k)
  • Ben Matone, Director of Investor Relations
  • Mr. Robert L. Crotty J.D., Gen. Counsel (Age 48)
  • Ms. Asli Gevgilili, Chief HR Officer
  • Mr. E. J. Brandreth MBA, Sr. VP of Quality Assurance
  • Dr. Jeffrey Skolnik, Sr. VP of Clinical Devel.
  • Mr. Robert J. Juba Jr., Sr. VP of Biological Manufacturing & Clinical Supply Management
  • Mr. Daniel Jordan, Sr. VP of Device Manufacturing Operations

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $1.89.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $432.89 million and generates $1.77 million in revenue each year. The biopharmaceutical company earns $-303.66 million in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals employs 317 workers across the globe.

When was Inovio Pharmaceuticals founded?

Inovio Pharmaceuticals was founded in 1979.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for Inovio Pharmaceuticals is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242.

This page (NASDAQ:INO) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.